Back to School: How biopharma can reboot drug development. Access exclusive analysis here

G3139: Phase I/II data; Phase III

Updated 1 year follow-up data from GNTA’s Phase

Read the full 83 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE